Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Growth in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,577,365 shares, an increase of 49.6% from the July 15th total of 1,054,620 shares. Based on an average trading volume of 1,913,836 shares, the short-interest ratio is presently 0.8 days. Currently, 22.5% of the company’s shares are short sold.

Moleculin Biotech Stock Performance

Shares of MBRX traded up $0.00 during midday trading on Tuesday, hitting $0.61. The company had a trading volume of 232,417 shares, compared to its average volume of 573,893. Moleculin Biotech has a 1 year low of $0.16 and a 1 year high of $15.75. The firm has a market capitalization of $4.33 million, a P/E ratio of -0.03 and a beta of 1.84. The company’s 50-day simple moving average is $1.99 and its 200-day simple moving average is $2.45.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Thursday, August 13th. The company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15. Equities analysts predict that Moleculin Biotech will post -3.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MBRX has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Wall Street Zen upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $22.00.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.